Par Pharmaceutical Companies PRX

Protalix BioTherapeutics ( PLX +0.7% ) says its the first patient has been treated in its Phase I/II clinical trials of PRX -102, its plant cell-expressed, chemically modified enzyme replacement therapy for the treatment of Fabry disease. Post your comment!

… yesterday received FTC permission for the deal, adding to EU authorization earlier this month. Under the conditions of the approval, Watson must sell 14 generic drugs to Par Pharmaceuticals ( PRX ) and four to Sandoz. ( PR ) Post your comment!

Sept 18 (Reuters) - Par Pharmaceutical Companies , Inc. on Tuesday sold $490 million of senior ..... bookrunning managers for the sale. BORROWER: PAR PHARMACEUTICAL COMPANIES , INC. AMT $490 MLN COUPON 7.375 PCT MATURITY …

… preliminary 'B+' corporate credit rating, on Woodcliff Lake, N.J.-based pharmaceutical company Par Pharmaceutical Companies Inc. remain unchanged following a change to deal terms. The changes include the $75 million upsize to …

… IPCI has a strategic alliance (10-year profit sharing agreement that begins with first sales of the drug) with Par Pharma ( PRX ), which agreed to a buyout by private equity firm TPG last month in a $1.9 billion deal. IPCI has settled patent litigation …

By Kapitall : Do you prefer to invest with a stock's trading momentum? We ran a screen with that idea in mind. We began by screening the drugmakers industry for stocks with strong momentum, trading within 5% of their 52-week highs. We then screened for those stocks with strong sales trends, ...